Company intelligence / Profile preview

Pheno Therapeutics

Edinburgh, Scotland, United Kingdomphenotherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Pheno Therapeutics has advanced its lead small molecule GPR17 antagonist candidate PTD802 into first-in-human clinical trials targeting remyelination in multiple sclerosis. The company leverages a proprietary phenotypic screening platform to identify novel neuroprotective agents focused on oligodendrocyte biology. No published clinical results yet; the company recently received regulatory approval to begin human studies.

Therapeutic areas: Neurology
Modalities: Small molecules (GPR17 antagonists)
Industry: Biotech

Drug pipeline

2 assets

PTD988

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

UCB (exclusive worldwide license agreement for PTD802 program)

Beyond the preview

Go deeper on Pheno Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pheno Therapeutics.

Explore the full profile